Thea Discepola
Vice President, Value Access & New Product Planning, Novartis Pharmaceuticals
As Vice-President, Value Access & New Product Planning at Novartis Pharmaceuticals Canada Inc., Thea Discepola manages a team at head office and across Canada that is responsible for ensuring that Novartis and its innovative medicines are known and understood by key stakeholders and that the medicines are readily available to Canadian patients through private and public drug plans. The team is responsible for health economics studies and outcomes research, provincial policy matters, pricing, reimbursement strategies, as well as new product planning.
Thea has been with Novartis for 20 years where she began her career as Legal Counsel in 2002. Over that period, she took on positions of increasing responsibilities within her field, managing a team accountable for legal, compliance and corporate matters for the Novartis Canada entity. She was eventually promoted to Vice-President of Legal, Compliance & Country General Counsel in 2013. Over and above her Legal duties, she took on the responsibilities of Ad Interim President at Novartis Pharma Canada in March 2019 for 4 months. Thea joined the Market Access team as Vice-President in March of 2020 just as the COVID-19 pandemic hit and has managed to successfully lead a team of almost 40 people virtually.
Thea brings to the team a high level of adaptability, curiosity, knowledge, drive and empathy along with an overall understating of the Canadian pharma organization which are key assets when facing the challenges in health policy and patient access in Canada.
Thea has a Law degree from the University of Montreal. She is trilingual and has a passion for travelling, music and spending time in nature.
As Vice-President, Value Access & New Product Planning at Novartis Pharmaceuticals Canada Inc., Thea Discepola manages a team at head office and across Canada that is responsible for ensuring that Novartis and its innovative medicines are known and understood by key stakeholders and that the medicines are readily available to Canadian patients through private and public drug plans. The team is responsible for health economics studies and outcomes research, provincial policy matters, pricing, reimbursement strategies, as well as new product planning.
Thea has been with Novartis for 20 years where she began her career as Legal Counsel in 2002. Over that period, she took on positions of increasing responsibilities within her field, managing a team accountable for legal, compliance and corporate matters for the Novartis Canada entity. She was eventually promoted to Vice-President of Legal, Compliance & Country General Counsel in 2013. Over and above her Legal duties, she took on the responsibilities of Ad Interim President at Novartis Pharma Canada in March 2019 for 4 months. Thea joined the Market Access team as Vice-President in March of 2020 just as the COVID-19 pandemic hit and has managed to successfully lead a team of almost 40 people virtually.
Thea brings to the team a high level of adaptability, curiosity, knowledge, drive and empathy along with an overall understating of the Canadian pharma organization which are key assets when facing the challenges in health policy and patient access in Canada.
Thea has a Law degree from the University of Montreal. She is trilingual and has a passion for travelling, music and spending time in nature.
